Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
untitled letter
Marketing
FDA posts untitled letter for emails with eye-catching graphics
The FDA accused QOL Medical of creating a misleading impression about the indication for the rare disease drug Sucraid.
Nick Paul Taylor
Jun 3, 2026 4:22am
BeOne TV drug ad hit by FDA over ‘misleading suggestions’
May 13, 2026 11:11am
Alnylam rebuked by FDA over efficacy claims on Amvuttra website
May 7, 2026 5:18am
Bayer earns FDA untitled letter for Nubeqa ad’s risk information
Apr 30, 2026 5:25am
Pfizer rebuked by FDA for misleading Adcetris ads on Facebook
Apr 14, 2026 4:22am
BMS, Novartis, Gilead, Iovance dinged in CBER untitled letters
Mar 30, 2026 10:00pm
